Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin in Pediatric Acute Leukemia
NCT07052994Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of revumenib in acute leukemia (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Dose Limiting Toxicity and Safety and Adverse Events. Planned start May 2026; status: withdrawn.
02
Drugs
revumenib
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT07052994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052994.